Welcome ISCT ESP Delegates
Re-engineering cell therapy with invariant Natural Killer T (iNKT) cells
An allogeneic, off‑the‑shelf CAR‑iNKT platform now entering first‑in‑human trials in Australia.
OUR PLATFORM
We engineer invariant Natural Killer T (iNKT) cells to deliver a multi-pronged attack against cancer. CAR-iNKT cells have multiple ways to kill cancer cells.
Engineered targeting via the CAR
Natural targeting vie NKG2D pathway and CD1d
Remodulate the tumour microenvironment
Activate T and NK cells
Learn more about our science →
OUR PROGRAMS
ALA-101
ALA-105
View pipeline and program details →
UPCOMING CLINICAL TRIAL
An Open label, phase 1 dose escalation trial evaluating the safety, tolerability and preliminary efficacy of ALA-101 in patients with relapsed or refractory lymphomas and leukaemias.
“There is a substantial unmet need for patients with relapsed or refractory haematological cancers, particularly for patients who have exhausted existing treatment options. ALA-101’s iNKT biology, combined with targeted CAR technology, is an innovative platform which addresses some of the challenges associated with existing cell therapies.”
To learn more about our trial, please contact us.
